29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Amsterdam, Netherlands

Webcast

 

Oral Presentation

Title: Favorable Response to Oral Ibrexafungerp (formerly SCY-078) in Patients with Refractory Fungal Diseases, Interim Analysis by Pathogen from a Phase 3 Open-label Study (FURI) 
Presenter: Oliver Cornely, MD
Date and Time: Tuesday, April 16, from 11:00-12:00 CET
Oral Presentation #: L0010 
Session: Recent clinical trials

Poster Presentations

Title: Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078) from the CARES Study 
Presenter: Deven Juneja, MD
Date and Time: Saturday, April 13, from 15:30-16:30 CET
Poster Presentation #: L0028
Session: Other issues and diverse late breaker aspects

Title: Favourable Clinical Outcome of Two Patients with Candida spp. Spondylodiscitis Treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study 
Presenter: Philipp Koehler, MD
Date and Time: Saturday, April 13, from 15:30-16:30 CET
Poster Presentation #: L0033
Session: Other issues and diverse late breaker aspects

Title: Use of Ibrexafungerp (formerly SCY-078) to Treat Severe Azole-refractory Oesophageal Candidiasis: A Case Report from the FURI Study 
Presenter: Jose Vazquez, MD
Date and Time: Saturday, April 13, from 15:30-16:30 CET
Poster Presentation #: P0125 
Session: Clinical pharmacokinetics, treatment strategies and prescribing of antifungals

Title: Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model 
Presenter: Annie Lee, PhD
Date and Time: Monday, April 15, from 11:42-11:47 CET
Poster Presentation #: O0740
Session: Antifungals: novel drugs, novel dosing?

Title: Efficacy of Ibrexafungerp (formerly SCY-078) against Pneumocystis Pneumonia in a Murine Therapeutic Model 
Presenter: Stephen Barat, PhD
Date and Time: Monday, April 15, from 11:00-11:05 CET
Poster Presentation #: O0733
Session: Antifungals: novel drugs, novel dosing?